Aromatase Inhibitors are drugs that prevent the formation of estradiol, a female hormone, by interfering with an aromatase enzyme. Aromatase inhibitors are used as a type of hormone therapy for postmenopausal women who have hormone-dependent breast cancer.
Marking the first major treatment advance since tamoxifen's introduction over 25 years ago, Canada's leading oncologists and breast cancer patient support and advocacy groups gathered to applaud a new era in treatment for early breast cancer.
Strategic partnerships between the pharmaceuticals industry and the biotechnology sector are making breast cancer therapeutics one of the most dynamic segments in the overall oncology market.
An updated analysis from an international clinical trial of the drug letrozole was presented on June 8, 2004 at the American Society of Clinical Oncology annual meeting in New Orleans.
Newest research findings were presented on the possible benefits they may provide for postmenopausal breast cancer risk reduction. SERMs are a class of drugs that can block the cell's ability to use estrogen to stimulate the development of breast cancer.
Women who regularly take aspirin seem to be at lower risk of the most common type of breast cancer than those who do not take aspirin, report researchers from Columbia University's Mailman School of Public Health and College of Physicians & Surgeons, Weill Cornell Medical College , and New York-Presbyterian Hospital.
A breast cancer drug made by Pfizer Inc. increased survival rates by 63 percent compared with the standard therapy tamoxifen, researchers said on Wednesday.
The clinical trial strengthens the case for administering the newer drug, exemestane, as a first option. A study published last week showed that women recovering from breast cancer lowered their chance of developing another tumor by 32 percent if they switched to exemestane after two or three years of tamoxifen treatment.